142 related articles for article (PubMed ID: 36433862)
1. Cell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.
Hanai T; Kawaratani H; Nagano J; Suii H; Sakamaki A; Arase Y; Nakanishi H; Kogiso T; Okubo T; Miwa T; Shimizu S; Hige S; Atsukawa M; Shimizu M; Kurosaki M; Terai S; Kagawa T; Tokushige K; Yoshiji H
Hepatol Res; 2023 Mar; 53(3):238-246. PubMed ID: 36433862
[TBL] [Abstract][Full Text] [Related]
2. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
[TBL] [Abstract][Full Text] [Related]
3. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study.
Bureau C; Adebayo D; Chalret de Rieu M; Elkrief L; Valla D; Peck-Radosavljevic M; McCune A; Vargas V; Simon-Talero M; Cordoba J; Angeli P; Rosi S; MacDonald S; Malago M; Stepanova M; Younossi ZM; Trepte C; Watson R; Borisenko O; Sun S; Inhaber N; Jalan R
J Hepatol; 2017 Nov; 67(5):940-949. PubMed ID: 28645737
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites.
Ito T; Hanafusa N; Soneda N; Isoai A; Kobayashi R; Torii N; Kato M
J Gastroenterol Hepatol; 2021 Nov; 36(11):3224-3232. PubMed ID: 34250635
[TBL] [Abstract][Full Text] [Related]
5. Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study.
Stepanova M; Nader F; Bureau C; Adebayo D; Elkrief L; Valla D; Peck-Radosavljevic M; McCune A; Vargas V; Simon-Talero M; Cordoba J; Angeli P; Rossi S; MacDonald S; Capel J; Jalan R; Younossi ZM
Qual Life Res; 2018 Jun; 27(6):1513-1520. PubMed ID: 29460201
[TBL] [Abstract][Full Text] [Related]
6. Management of cirrhotic ascites: Seven-step treatment protocol based on the Japanese evidence-based clinical practice guidelines for liver cirrhosis 2020.
Yoshiji H
Hepatol Res; 2023 Jun; ():. PubMed ID: 37332123
[TBL] [Abstract][Full Text] [Related]
7. Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study.
Yamada Y; Inui K; Hara Y; Fuji K; Sonoda K; Hashimoto K; Kamijo Y
Sci Rep; 2019 Jul; 9(1):10195. PubMed ID: 31308465
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites.
Yokomichi N; Imai K; Sakamoto M; Horiki M; Yamauchi T; Miwa S; Inoue S; Uneno Y; Suzuki H; Wada T; Ichikawa Y; Morita T
BMC Cancer; 2022 Feb; 22(1):218. PubMed ID: 35227250
[TBL] [Abstract][Full Text] [Related]
9. Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites.
Zaak D; Paquet KJ; Kuhn R
Z Gastroenterol; 2001 Jan; 39(1):5-10. PubMed ID: 11215366
[TBL] [Abstract][Full Text] [Related]
10. Large volume paracentesis and intravenous dextran to treat tense ascites.
Acharya SK; Balwinder S; Padhee AK; Nijhawan S; Tandon BN
J Clin Gastroenterol; 1992 Jan; 14(1):31-5. PubMed ID: 1372924
[TBL] [Abstract][Full Text] [Related]
11. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites.
Neong SF; Adebayo D; Wong F
Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):293-305. PubMed ID: 30791777
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of large volume paracentesis in cirrhotic patients with spontaneous bacterial peritonitis: a randomized prospective study].
Choi CH; Han KH; Kim DY; Cho JH; Cheong JY; Song KH; Chon CY; Moon YM
Taehan Kan Hakhoe Chi; 2002 Mar; 8(1):52-60. PubMed ID: 12499817
[TBL] [Abstract][Full Text] [Related]
13. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
[TBL] [Abstract][Full Text] [Related]
14. CART: Cell-free and Concentrated Ascites Reinfusion Therapy against malignancy-related ascites.
Ito T; Hanafusa N
Transfus Apher Sci; 2017 Oct; 56(5):703-707. PubMed ID: 28916401
[TBL] [Abstract][Full Text] [Related]
15. Large-volume cell-free and concentrated ascites reinfusion therapy improves venous flow in patients with liver cirrhosis.
Matsumoto N; Ogawa M; Kanda T; Matsuoka S; Moriyama M; Matsusaki K
J Med Ultrason (2001); 2021 Jul; 48(3):315-322. PubMed ID: 33835337
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial.
García-Compean D; Blanc P; Larrey D; Daures JP; Hirtz J; Mendoza E; Maldonado H; Michel H
Ann Hepatol; 2002; 1(1):29-35. PubMed ID: 15114293
[TBL] [Abstract][Full Text] [Related]
17. Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis.
Kozaki K; IInuma M; Takagi T; Fukuda T; Sanpei T; Terunuma Y; Yatabe Y; Akano K
Ther Apher Dial; 2016 Aug; 20(4):376-82. PubMed ID: 27523078
[TBL] [Abstract][Full Text] [Related]
18. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
[TBL] [Abstract][Full Text] [Related]
19. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.
Yorioka N; Namisaki T; Shibamoto A; Suzuki J; Kubo T; Iwai S; Tomooka F; Tanaka M; Takeda S; Fujimoto Y; Enomoto M; Muarata K; Inoue T; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yamazaki M; Yoshiji H
In Vivo; 2023; 37(3):1226-1235. PubMed ID: 37103093
[TBL] [Abstract][Full Text] [Related]
20. Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer.
Maeda O; Ando T; Ishiguro K; Watanabe O; Miyahara R; Nakamura M; Funasaka K; Kazuhiro F; Ando Y; Goto H
Mol Clin Oncol; 2014 Nov; 2(6):1103-1106. PubMed ID: 25279205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
